Market Overview

Why Goldman Sachs Added Iqvia To Its 'Conviction Buy' List

Share:
Why Goldman Sachs Added Iqvia To Its 'Conviction Buy' List
Related
Benzinga's Top Upgrades, Downgrades For January 18, 2019
Earnings Scheduled For October 22, 2018

For the second time in a week, Goldman Sachs updated its Conviction Buy list, this time adding Iqvia Holdings Inc (NYSE: IQV).

The Analyst

Goldman analyst Robert Jones reiterated his Buy rating for Iqvia and lowered his price target from $152 to $151.

The Thesis

The outlook for contract research organizations like Iqvia is strong heading into 2019.

Jones said Iqvia has the most upside in the CRO group due to its attractive valuation and its potential to beat consensus revenue estimates in coming quarters. He said Iqvia will hit an inflection point on revenue growth this year, and the stock currently trades at a discount to peers and its own multiple in terms of its two-year forward PEG ratio.

In addition, Jones said a reduction in secondary offerings should help stabilize the stock and pave the way for a decline in net leverage.

Jones says some CRO investors are concerned about the potential for a slowdown in biotech demand, are worried about the durability of CRO backlogs given large-scale pharma M&A and are troubled by the possibility of a global macro slowdown. However, he says Iqvia is well-positioned despite the concerns.

“IQV is the best positioned on exposure to customer concentration (a concern relating to Pharma M&A) and ‘emerging biotech’ vs CRO peers - 2 areas of investor concern for the group,” he wrote in the note.

Jones said public/private funding, R&D growth and FDA approvals, three drivers of demand growth for CROs, are all looking healthy at the moment.

Price Action

Iqvia shares traded lower by 1.5 percent to $121.50 Friday afternoon.

Related Links:

Goldman Sachs Adds Netflix To 'Conviction Buy' List

Analysts Love CVS Health Shares Following Aetna Deal

Latest Ratings for IQV

DateFirmActionFromTo
Jan 2019JefferiesUpgradesHoldBuy
Dec 2018Morgan StanleyMaintainsOverweightOverweight
Oct 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for IQV
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Robert JonesAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (IQV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MDRXKeyBancUpgrades0.0
ANETNomuraUpgrades260.0
CNPRBC CapitalUpgrades34.0
FISVOppenheimerUpgrades88.0
FNDUBSUpgrades37.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Germany Says It's "Ready" To Build Infrastructure To Import U.S. LNG

Not Enough New Year's Resolve: JPMorgan Downgrades Weight Watchers